The Oncology Institute, Inc.
NASDAQ:TOI
2.5 (USD) • At close April 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 393.412 | 324.239 | 252.483 | 203.003 | 187.515 | 155.405 | 113.16 |
| Cost of Revenue
| 0 | 264.666 | 200.39 | 162.155 | 150.636 | 125.465 | 86.879 |
| Gross Profit
| 393.412 | 59.573 | 52.093 | 40.848 | 36.879 | 29.941 | 26.282 |
| Gross Profit Ratio
| 1 | 0.184 | 0.206 | 0.201 | 0.197 | 0.193 | 0.232 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0.309 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 41.588 | 0 | 0 |
| SG&A
| 107.828 | 113.851 | 119.689 | 83.365 | 41.897 | 29.644 | 20.389 |
| Other Expenses
| 345.702 | 22.74 | 4.411 | 3.341 | 3.178 | 2.942 | 1.103 |
| Operating Expenses
| 453.53 | 136.591 | 124.1 | 86.706 | 45.075 | 32.585 | 21.492 |
| Operating Income
| -60.118 | -77.018 | -72.007 | -45.858 | -8.196 | -2.635 | 4.79 |
| Operating Income Ratio
| -0.153 | -0.238 | -0.285 | -0.226 | -0.044 | -0.017 | 0.042 |
| Total Other Income Expenses Net
| -4.545 | -6.086 | 81.86 | 34.26 | -6.618 | 0.007 | 0.071 |
| Income Before Tax
| -64.663 | -83.104 | 1.904 | -11.598 | -14.814 | -2.638 | 4.861 |
| Income Before Tax Ratio
| -0.164 | -0.256 | 0.008 | -0.057 | -0.079 | -0.017 | 0.043 |
| Income Tax Expense
| 0 | -0.036 | 0.247 | -0.671 | -0.493 | 1.383 | 0.913 |
| Net Income
| -64.663 | -83.068 | 1.657 | -10.927 | -14.321 | -4.021 | 3.948 |
| Net Income Ratio
| -0.164 | -0.256 | 0.007 | -0.054 | -0.076 | -0.026 | 0.035 |
| EPS
| -0.001 | -0.92 | 0.023 | -0.16 | -0.24 | -0.062 | 0.14 |
| EPS Diluted
| -0.001 | -0.92 | 0.021 | -0.16 | -0.24 | -0.062 | 0.14 |
| EBITDA
| -50.88 | -70.454 | 8.402 | -7.937 | -11.29 | 0.307 | 9.077 |
| EBITDA Ratio
| -0.129 | -0.217 | 0.033 | -0.039 | -0.06 | 0.002 | 0.08 |